US buys 30,000 courses of intravenous antivirals for H1N1 - updated
This article was originally published in Scrip
BioCryst Pharmaceuticals has shipped 10,000 treatment courses of its intravenous antiviral peramivir to the US health and human services (HHS) department under a $22.5 million contract aimed at countering the toll of H1N1 influenza. The order came less than two weeks after the FDA authorised peramivir, an unapproved drug, for emergency use in hospitalised H1N1 patients (scripnews.com, October 26th, 2009).
You may also be interested in...
Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
Agency is working with manufacturers, including Takeda and Emergent BioSolutions, to accelerate development of hyperimmune globulin products, with an eye toward starting clinical testing in several months; new FDA guidelines on convalescent plasma collection for single-patient emergency IND use are helpful in understanding agency expectations around source plasma collection for manufactured products as well, Emergent SVP Laura Saward says.